Observational studies of drug-eluting stents - Some are more equal than others

EuroIntervention

Volumn 4, Issue 4, 2009, Pages 419-423

  Austin, David ^a,b   Oldroyd, Keith G ^c   Pell, Jill P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^c Lung Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; METAL; PACLITAXEL; RAPAMYCIN;

CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; HUMAN; INSTRUMENTATION; MORTALITY; NETHERLANDS; NOTE; REGISTER; RISK ASSESSMENT; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; HUMANS; METALS; NETHERLANDS; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK ASSESSMENT; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 63049100169     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV4I4A73     Document Type: Editorial

References (14)

1. Cook S, Meier B. Have we been misled by the ESC DES firestorm? Eurointerv. 2008;3: 535-537.
2. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369: 667-678.
3. Win HKM, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MAM, Granada JFM, Marulkar S, Nassif D, Cohen DJM, Kleiman NS, for the EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297: 2001-2009.
4. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2006;297: 159-168.
5. Daemen J, van Twisk P-H, Kukreja N, van Domburg RT, Boersma E, de Jaegere PP, Serruys PW. The relative safety and efficacy of bare-metal and drug-eluting stents in low and high risk patient subsets. EuroInterv. 2008;4: 464-474.
6. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol. 1999;34: 618-620.
7. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: Compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epid. 1995;48: 1441-1452.
8. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370: 937-948.
9. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357: 1393-1402.
10. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation. 2007;115: 3181-3188.
11. Austin D, Oldroyd KG, McConnachie A, Slack R, Eteiba H, Flapan AD, Jennings KP, Northcote RJ, Pell ACH, Starkey IR, Pell JP. Drug-eluting stents versus bare-metal stents for off-label indications: a propensity score-matched outcome study. Circ Cardiovasc Intervent. 2008;1: 45-52.
12. Shishehbor MH, Goel SS, Kapadia S, Bhatt DL, Kelly P, Raymond RE, Galla JM, Brener SJ, Whitlow PL, Ellis SG. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol. 2008;52: 1041-1048.
13. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359: 1330-1342.
14. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28: 2706-13.